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Many kallikrein genes were found to be differentially expressed in various malignancies, and prostate speciﬁc antigen (encoded
by the KLK3 gene) is the best tumour marker for prostate cancer. Prostate speciﬁc antigen has recently been shown to be an
independent favourable prognostic marker for breast cancer. KLK15 is newly discovered kallikrein gene that is located adjacent
to KLK3 on chromosome 19q13.4. KLK15 has 41% similarity to KLK3 and the encoded protein, hK15, can activate pro-
prostate speciﬁc antigen. We studied the expression of KLK15 by real-time quantitative reverse transcriptase–polymerase
chain reaction in 202 tissues from patients with breast carcinoma of various stages, grades and histological types. KLK15
expression was found to be a signiﬁcant predictor of progression-free survival (hazard ratio of 0.41 and P=0.011) and overall
survival (hazard ratio of 0.34 and P=0.009). When all other known confounders were controlled in the multivariate analysis,
KLK15 retained its prognostic signiﬁcance. Higher concentrations of KLK15 mRNA were found more frequently in node
negative patients (P=0.042). No association was found between KLK15 expression and any other clinicopathological variable.
Further, KLK15 is an independent prognostic factor of progression-free survival and overall survival in the subgroup of patients
with lower grade and those with oestrogen receptor and progesterone receptor negative tumours in both univariate and
multivariate analysis. KLK15 levels of expression were slightly higher (although not statistically signiﬁcant) in the oestrogen
receptor negative and progesterone receptor negative subgroups of patients. KLK15 is up-regulated by androgens in breast
cancer cell lines. Time-course and blocking experiments suggest that this regulation is mediated through the androgen
receptor.
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The human kallikrein gene family includes 15 serine protease
genes, clustered on chromosome 19q13.4. Many kallikreins were
found to be differentially expressed in endocrine-related malignan-
cies (Diamandis and Yousef, 2001; Yousef and Diamandis, 2001).
KLK10 (also known as the normal epithelial cell-speciﬁc 1 gene,
NES1) appears to be a novel tumour suppressor, which is down-
regulated during breast cancer progression (Goyal et al, 1998).
KLK6 (zyme/ protease M/neurosin) is overexpressed in primary
breast and ovarian cancers (Anisowicz et al, 1996) and preliminary
studies indicate that it may have utility as a serum biomarker for
ovarian carcinoma (Diamandis et al, 2000). Two additional kallik-
rein genes, KLK8 (also known as neuropsin or TADG-14)
(Underwood et al, 1999; Magklara et al, 2001) and the stratum
corneum chymotryptic enzyme (Tanimoto et al, 1999; Yousef et
al, 2000c) are up-regulated in ovarian cancer. KLK12, KLK15 and
KLK13 seem to be down-regulated in breast cancer (Yousef et al,
2000a,b; 2001a).
The gene encoding for prostate speciﬁc antigen, KLK3,i sa
member of the human kallikrein family and is located at the
centromeric side of the locus. KLK3 is ﬂanked by the KLK2 gene
(encoding for human glandular kallikrein protein; hK2), and by
the KLK15 (Yousef et al, 2001b). In addition to its wide applicabil-
ity as the best marker for prostate cancer (Diamandis, 1998), hK3,
was recently found to be expressed in other tissues, including the
female breast (Black and Diamandis, 2000). Prostate speciﬁc anti-
gen (PSA) protein in tumour cytosols was found to be an
independent marker for favourable prognosis in breast cancer
(Yu et al, 1995). KLK15 (encoding for hK15, a protein also named
‘prostinogen’) is the most recently cloned member of the human
kallikrein gene family (Takayama et al, 2001; Yousef et al,
2001b). It is formed of ﬁve coding exons and encodes for a serine
protease of a predicted molecular weight of about 28 kDa. KLK15
shares a high degree of structural similarity with KLK3 and other
kallikreins. At the protein level, hK15 has 40% identity and 53%
similarity with hK3, which is comparable to the degree of similarity
between hK3 and other kallikreins (except hK2). It also has *50%
similarity with hK9 and hK11. Similarly to hK3, but unlike other
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due in the substrate-binding pocket, suggesting a chymotrypsin-like
substrate speciﬁcity. We have previously shown preliminarily that
KLK15 is up-regulated, at the mRNA level, in prostate cancer
(Yousef et al, 2001b). A recent report indicated that hK15 can
readily activate the precursor of PSA by cleaving an amino terminal
peptide bond (Takayama et al, 2001).
In this article we report for the ﬁrst time that KLK15, like KLK3,
is an independent favourable prognostic marker for breast cancer.
We further investigated the mechanism that regulates KLK15
expression in breast cancer cell lines and provide evidence that
KLK15 is up-regulated by androgens through the androgen recep-
tor pathway.
MATERIALS AND METHODS
Study population
Included in this study were tumour specimens from 202 consecu-
tive patients undergoing surgical treatment for primary breast
carcinoma at the Department of Gynecologic Oncology at the
University of Turin, Turin, Italy. All specimens were histologically
conﬁrmed. Tumour tissues had been frozen in liquid nitrogen
immediately after surgery. This study has been approved by the
Institutional Review Board of the University of Turin. The patient
ages ranged from 25 to 87 with a median of 57 years. Tumour
sizes ranged from 0.1 to 15 cm with a median of 2.2 cm.
Follow-up information was available for 190 patients (median
follow-up period 78 months), among whom 58 (31%) had
relapsed and 48 (25%) died. Local relapses (i.e. ipsilateral breast
after breast conserving surgery) or relapses in soft tissues (chest
wall after mastectomy or in subclavicular lymphnodes) were diag-
nosed clinically or radiologically and then always conﬁrmed
cytologically/histologically by ﬁne needle aspiration or core biopsy.
Visceral metastases (lung, liver) were assessed histologically only
when their nature was deemed as equivocal on ultrasound (US),
computed tomography (TC) and nuclear magnetic resonance
(RMN) evaluation. Bone metastasis were detected clinically or by
routine bone scans and then always conﬁrmed by radiograms,
TC or RMN. The histological type and steroid hormone receptor
status of each tumour as well as the number of positive axillary
nodes were established at the time of surgery, as shown in Table
1. Out of the 202 patients, 121 (60%) had ductal carcinoma, 34
(17%) lobular carcinoma and 44 (22%) had other histological
types (the histological type was not known for three patients).
Patients from clinical stages I–III were included in the study, with
clinical staging determined according to the TNM classiﬁcation.
Grading of tumours was done according to the Bloom-Scarff-
Richardson grading system (Bloom and Richardson, 1957).
Forty-four patients (22%) received no adjuvant treatment, 92
(46%) received tamoxifen, and 66 (33%) received chemotherapy
with or without tamoxifen. Oestrogen receptor (ER) and proges-
terone receptor (PR) status was established as described by the
European Organization for Research and Treatment of Cancer
(EORTC, (1980)).
Total RNA extraction and cDNA synthesis
Tumour tissues were minced with a scalpel, on dry ice, and trans-
ferred immediately to 2 ml polypropylene tubes. They were then
homogenised and total RNA was extracted using TrizolTM reagent
(Gibco BRL) following the manufacturer’s instructions. The
concentration and purity of mRNA were determined spectrophoto-
metrically. Two micrograms of total RNA was reverse-transcribed
into ﬁrst strand cDNA using the Superscript
TM preampliﬁcation
system (Gibco BRL). The ﬁnal volume was 20 ml.
Quantitative real-time polymerase chain reaction and
continuous monitoring of polymerase chain reaction
products
Based on the published genomic sequence of KLK15 (GenBank
accession no. AF242195), two gene-speciﬁc primers were designed
(15-F3: 5'-TGT GGC TTC TCC TCA CTC TC-3' and 15-R3 5'-
AGG CTC GTT GTG GGA CAC-3'). These primers spanned more
than two exons to avoid contamination by genomic DNA.
Real-time monitoring of polymerase chain reaction (PCR) reac-
tion was done using the LightCycler
TM system (Roche Molecular
Systems, Indianapolis, USA) and the SYBR Green I dye, which
binds preferentially to double stranded DNA. Fluorescence signals
are proportional to the concentration of the product and are
measured at the end of each cycle rather than after a ﬁxed number
of cycles. The higher the starting quantity of the template, the
earlier a signiﬁcant increase in ﬂuorescence is observed (Bieche et
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Table 1 Relationships between KLK15 status
a and other variables
No. of patients (%)
Variable Total KLK15-negative KLK15-positive P value
Age (years)
545 39 28 (71.8) 11 (28.2)
45–55 52 40 (76.9) 12 (23.1) 0.28
d
455 111 72 (64.9) 39 (35.1)
Menopausal status
Pre/peri 67 50 (74.6) 17 (55.4) 0.16
e
Post 135 90 (66.7) 45 (33.3)
Tumor size (cm)
52 91 65 (71.4) 26 (28.6) 0.33
e
52 111 75 (67.6) 36 (32.4)
Nodal status
Negative 88 56 (63.6) 32 (36.4) 0.042
e
Positive 101 77 (76.2) 24 (23.8)
x1 3
Stage
c
I 85 60 (70.6) 25 (29.4)
II 80 55 (68.8) 25 (31.3) 0.48
d
III 22 18 (81.8) 4 (18.2)
x1 5
Grade
b
I 85 63 (74.1) 22 (25.9)
II 65 41 (63.1) 24 (36.9) 0.32
e
III 47 34 (72.3) 13 (27.7)
x5
Histology
Ductal 121 84 (69.4) 37 (30.6)
Lobular 34 26 (76.5) 8 (23.5) 0.59
d
Other 44 29 (65.9) 15 (34.1)
x3
ER status
Negative 72 50 (69.4) 22 (30.6) 0.53
e
Positive 123 86 (69.9) 37 (30.1)
x7
PR status
Negative 91 63 (69.2) 28 (30.8) 0.51
e
Positive 104 73 (70.2) 31 (29.8)
x7
Adjuvant treatment
None 44 30 (68.2) 14 (31.8)
Tamoxifen 92 61 (66.3) 31 (33.7)
Chemotherapy+tamoxifen 66 49 (74.2) 17 (25.8) 0.55
d
aCutoff point: 70
th percentage.
b Bloom-Scarff-Richardson grading system.
cTNM
system.
dw
2 test.
eFisher’s Exact Test. x, Status is unknown.
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number at which ﬂuorescence passes a ﬁxed threshold above base-
line. For each sample, the amount of the target and of an
endogenous control (b actin, a housekeeping gene) were deter-
mined using a calibration curve (see below). The amount of the
target molecule was then divided by the amount of the endogenous
reference, to obtain a normalised target value.
Standard curve construction
The full-length mRNA sequence of the KLK15 gene was ampliﬁed
by PCR using gene-speciﬁc primers, and the PCR product was
cloned into the TOPO TA cloning vector (Invitrogen, Carlsbad,
CA, USA) according to manufacturer’s instructions. Plasmid was
puriﬁed using a Mini-prep kit (Qiagen Inc., Valencia, CA, USA).
Different standard curves for actin and KLK15 were constructed
using serial dilutions of the plasmid as described elsewhere (Bieche
et al, 1999). The standard curve samples were included in each run.
The LightCycler software automatically calculates the standard
curve by plotting the starting dilution of each standard sample vs
the threshold cycle, and the sample concentrations were then calcu-
lated accordingly (Figure 1).
PCR ampliﬁcation
The PCR reaction was carried out on the LightCycler
TM system.
For each run, a master mixture was prepared on ice, containing
1 ml of cDNA, 2 ml of LC DNA Master SYBR Green 1 mix,
50 ng of primers and 1.2 mlo f2 5m M MgCl2. After the reaction
mixture was loaded into the glass capillary tube, the cycling condi-
tions were carried out as follows: initial denaturation at 948C for
10 min, followed by 45 cycles of denaturation at 948C for 0 s,
annealing at 638C for 5 s, and extension at 728C for 30 s. The
temperature transition rate was set at 208Cs
71. Fluorescent
product was measured by a single acquisition mode at 888C after
each cycle. A melting curve was then performed by holding the
temperature at 708C for 30 s followed by a gradual increase in
temperature to 988C at a rate of 0.28Cs
71, with the signal acquisi-
tion mode set at step. To verify the melting curve results,
representative samples of the PCR products were sequenced.
Statistical analysis
Patients were subdivided into groups based on different clinical or
pathologic parameters and statistical analyses were performed using
SAS software (SAS Institute, Cary, NC, USA). A cutoff point equal
to the detection limit (70th percentile) was used. According to this
cutoff, KLK15 expression was classiﬁed as positive or negative and
associations between KLK15 status and other qualitative variables
were analysed using the chi-square (w
2) or the Fisher’s Exact Test,
where appropriate. The analysis of differences in KLK15 values
between groups of patients was performed with the non-parametric
Mann-Whitney U-test or Kruskal-Wallis tests. In this analysis,
KLK15 was used as a continuous variable. The cutoff value for
tumour size was 2 cm. Lymph node status was either positive
(any positive number of nodes) or negative. Age was categorised
into three groups: less than 45 years, 45 to 55 years and greater
than 55 years. Survival analyses were performed by constructing
Kaplan-Meier DFS and OS curves (Kaplan and Meier, 1958) and
differences between curves were evaluated by the log-rank test, as
well as by estimating the relative risks for relapse and death using
the Cox proportional hazards regression model (Cox, 1972). Cox
analysis was conducted at both univariate and multivariate levels.
Only patients for whom the status of all variables was known were
included in the multivariate regression models, which incorporated
KLK15 and all other variables for which the patients were charac-
terised. The multivariate models were adjusted for patient age,
nodal status (pathological nodal classiﬁcation), tumour size, grade,
histological type and ER and PR status.
Breast cancer cell lines and hormonal stimulation
experiments
In order to test the hypothesis that KLK15 is under steroid hormo-
nal regulation, we examined the effect of different steroids on
KLK15 expression in different cell line models. The breast cancer
cell lines BT-474, BT-20 and MCF-7 were purchased from the
American Type Culture Collection (ATCC, Rockville, MD, USA).
Cells were cultured in RPMI media (Gibco BRL, Gaithersburg,
MD, USA) supplemented with glutamine (200 mmol l
71), foetal
bovine serum (10%), in plastic ﬂasks, to near conﬂuency. The cells
were then aliquoted into 24-well tissue culture plates and cultured
to 50% conﬂuency. Twenty-four hours before the experiments, the
culture media were changed into media containing 10% charcoal-
stripped foetal bovine serum. For stimulation experiments, various
steroid hormones dissolved in 100% ethanol were added into the
culture media, at a ﬁnal concentration of 10
78 M. Cells stimulated
with 100% ethanol were included as controls. The cells were grown
for 24 h, then harvested for mRNA extraction.
Blocking and kinetic experiments
In order to examine whether KLK15 regulation occurs directly
through the androgen receptor (AR), blocking and kinetic experi-
ments were performed. Blocking experiments were performed as
follows: (a) stimulation by the AR blocker alone (two AR blockers
were used: RU56,187 and nilutamide), at three different concentra-
tions (10
76–10
78 M), (b) Stimulation of cells by
dihydrotestosterone (DHT) alone at a concentration of 10
78 M.
These concentrations were chosen based on our previous dose-
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Figure 1 Quantiﬁcation of KLK15 gene expression by real-time PCR.
(Top) A logarithmic plot of ﬂuorescence signal above the noise level (hor-
izontal line) during ampliﬁcation. Serial dilutions of a plasmid containing the
KLK15 cDNA were made and an arbitrary copy number was assigned to
each sample according to the dilution factor. (Bottom) The crossing points
(cycle number), plotted against the log of copy number to obtain a stan-
dard curve. For details, see text.
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British Journal of Cancer (2002) 87(11), 1294–1300 ã 2002 Cancer Research UKresponse studies for KLK15 in the same cell lines (Zarghami et al,
1997; Magklara et al, 2000). (c) Addition of the blocker to the cells
at three different concentrations, incubation for 1 h and then
adding DHT at 10
78 M. Ethanol-only stimulated cells were
included as controls in order to assess baseline KLK15 expression.
Cells were harvested for analysis after 24 h. For kinetic experi-
ments, the BT-474 cell line was stimulated with DHT at a ﬁnal
concentration of 10
78 M and then harvested at 0, 2, 6, 12 and
24 h. Control cells with ethanol alone were included for all time
points. All experiments were repeated twice.
RESULTS
KLK15 and breast cancer survival
Out of the 202 patients included in this study, follow-up informa-
tion was available for 190 patients, among whom 58 (31%) had
relapsed and 48 (25%) died. Of 202 breast tumours examined,
62 (30%) were classiﬁed as positive for KLK15 expression. In Table
1 we present the association of KLK15 status of the tumour (nega-
tive or positive) with various clinicopathological variables. We
found no statistically signiﬁcant associations between KLK15 status
and age, menopausal status, tumour size, stage (despite a trend for
stage III patients to be less frequently KLK15-positive), grade,
histological type, ER or PR status and adjuvant chemotherapy.
However, node-negative patients were more frequently KLK15-
positive (P=0.042).
The strength of the association between each clinicopathological
variable and the progression-free survival (PFS) and overall survival
(OS) are shown in the univariate analysis of Table 2. Nodal status,
tumour size, stage and grade of the disease and steroid hormone
receptor status were signiﬁcant predictors for the PFS and OS, as
expected. In addition to these known factors, KLK15 expression
was found to be a signiﬁcant predictor of progression-free survival
(hazard ratio of 0.41 and P=0.011) and overall survival (hazard
ratio of 0.34 and P= 0.009). Kaplan-Meier survival curves (Figure
2) also demonstrate that patients with KLK15 positive tumours
have signiﬁcantly longer progression-free survival (P=0.008)
compared to those who are KLK15 negative. Similar results were
found with respect to the overall survival (P=0.006) (Figure 2B).
When all parameters were included in the Cox model (multi-
variate analysis, Table 2), nodal status and tumour size retained
their prognostic signiﬁcance. KLK15 expression also retained its
PFS and OS prognostic signiﬁcance (hazard ratio of 0.39 and
0.34, and P value of 0.017 and 0.016, respectively). A weak associa-
tion of OS with PR was also seen (P=0.028).
Table 3 shows Cox proportional hazard regression analysis for
KLK15 expression in breast cancer patients stratiﬁed by tumour
grade, nodal status, tumour size, and ER and PR status. After
adjusting for known prognostic confounders, KLK15 was found
to be a signiﬁcant prognostic factor for both PFS and OS in the
subgroup of patients with low grade (grade I–II) and those with
ER-negative and PR-negative tumours. Hazard ratios derived from
the Cox regression analysis and related to PFS and OS were 0.37
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Table 2 Prognostic value of KLK15 expression in breast cancer.
Univariate analysis
Progression-free survival Overall survival
Variable HR
a 95% CI
b P value HR
a 95% CI
b P value
KLK15
Negative 1.00 1.00
Positive 0.41 0.21–0.81 0.011 0.34 0.15–0.76 0.009
Nodal status 5.11 2.58–10.1 50.001 7.01 2.98–16.5 50.001
Tumour size 1.41 1.26–1.57 50.001 1.35 1.22–1.50 50.001
Stage
c (ordinal) 4.1 2.75–6.1 50.001 3.78 2.48–5.75 50.001
Grading (ordinal) 1.65 1.19–2.27 0.002 1.94 1.36–2.76 50.001
ER status 0.59 0.35–0.98 0.043 0.42 0.24–0.72 0.002
PR status 0.53 0.32–0.89 0.016 0.37 0.21–0.66 50.001
Histologic type
d 0.79 0.60–1.04 0.094 0.76 0.55–1.03 0.081
Age 0.98 0.96–1.01 0.15 0.99 0.97–1.01 0.46
Multivariate analysis
Negative 1.00 1.00
Positive 0.39 0.18–0.85 0.017 0.34 0.14–0.82 0.016
Nodal status 4.02 1.96–8.26 50.001 6.10 2.50–14.87 50.001
Tumor size 1.27 1.13–1.44 50.001 1.21 1.07–1.37 0.002
Grading (ordinal) 1.11 0.69–1.75 0.65 1.22 0.73–2.04 0.44
ER status 0.84 0.41–1.54 0.64 0.72 0.33–1.57 0.42
PR status 0.63 0.31–1.28 0.21 0.40 0.18–0.91 0.028
Histological type
d 0.86 0.51–1.47 0.58 0.96 0.51–1.81 0.91
Age 0.99 0.96–1.01 0.45 1.00 0.97–1.03 0.85
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConﬁdence interval of the estimated HR.
cTNM system.
dLobular and others vs
ductal.
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Figure 2 Kaplan-Meier survival curves showing progression-free survival
(PFS) (A) and Overall survival (OS) (B) for patients with KLK15 positive
and KLK15 negative tumours. For details, see text.
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grade tumours, 0.25 (P=0.015) and 0.23 (P=0.016), respectively,
for ER negative tumours, and 0.24 (P=0.012) and 0.25
(P=0.016), respectively, for PR-negative tumours.
Hormonal regulation of the KLK15 gene
In order to explore the mechanism of KLK15 gene regulation, we
identiﬁed the promoter of this gene by aligning its genomic
sequence against the Human Genome Project sequence database.
DNA sequence analysis using different promoter detection algo-
rithms indicated the presence of a putative androgen response
element (GGGACAgggGGTCCT) at position 7298. This element
is comparable to the consensus androgen response element (GG
(T/A) ACAnnnTGTTCT). Interestingly, two of the three nucleo-
tides that are different from the consensus ARE (underlined) are
also different in the response elements of both PSA and KLK2.
We thus hypothesised, as is the case with other kallikreins, that
KLK15 may be up-regulated by androgens through the AR path-
way.
In order to test this hypothesis, we examined KLK15 expression
in three breast cancer cell lines with variable receptor content. As
shown in Figure 4, KLK15 was up-regulated by androgens
(DHT) and, to a lesser extent, by progestins in the steroid
hormone receptor-positive BT-474 cell line. On the other hand,
no signiﬁcant up-regulation of KLK15 expression was found in
the BT-20 cell line, which is known to be devoid of steroid
hormone receptors. Also, the MCF-7 cell line did not show any
up-regulation of KLK15 expression with either androgens or
progestins (Figure 3). We have previously conﬁrmed, by Western
blot and ligand binding assays, that the cell line has very low
androgen receptor content (our data, submitted for publication).
Kinetic studies with BT-474 cells showed that KLK15 up-regulation
was detectable as early as 2 h after hormonal stimulation and the
level increased gradually over time up to 24 h (Figure 4). These
results are similar to those previously reported for KLK2 and
KLK3 in the same cell lines (Magklara et al, 2000). In order to
further conﬁrm that this androgen up-regulation occurs through
the AR, we conducted blocking experiments, as described in details
in Materials and Methods (Figure 5). Both anti-androgens used
(RU 56,187 and nilutamide) were able to block the stimulatory
effect of DHT (by about 50–77%). Taken together, these data
suggest that KLK15 is up-regulated by androgens through the AR
pathway.
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Table 3 Cox proportional hazard regression analysis for subgroups of patients with breast cancer.
Progression-free survival Overall survival
Variable HR
a 95% CI
b P value HR
a 95% CI
b P value
Grade I-II
KLK15 unadjusted 0.41 0.17–0.97 0.042 0.26 0.078–0.86 0.027
KLK15 adjusted
d 0.37 0.14–0.98 0.045 0.21 0.062–0.72 0.013
Grade III
KLK15 unadjusted 0.51 0.16–1.52 0.21 0.55 0.18–1.66 0.29
KLK15 adjusted
d 0.23 0.06–0.87 0.031 0.35 0.11–1.18 0.092
Node negative
KLK15 unadjusted 0.19 0.024–1.52 0.11 0.24 0.023–2.61 0.29
KLK15 adjusted
e 0.16 0.021–1.35 0.093 0.74 0.21–2.67 0.65
Node positive
KLK15 unadjusted 0.52 0.23–1.18 0.12 0.51 0.21–1.24 0.14
KLK15 adjusted
e 0.44 0.19–1.03 0.058 0.38 0.15–0.96 0.042
Tumor size 42cm
KLK15 unadjusted 0.26 0.06–1.12 0.071 0.28 0.022–3.7 0.15
KLK15 adjusted
c 0.25 0.03–2.05 0.19 0.94 0.15–5.65 0.94
Tumor size 42cm
KLK15 unadjusted 0.45 0.21–0.98 0.044 0.46 0.21–1.06 0.072
KLK15 adjusted
c 0.44 0.18–1.07 0.071 0.42 0.17–0.97 0.046
ER-positive
KLK15 unadjusted 0.43 0.18–1.06 0.068 0.26 0.11–0.62 0.002
KLK15 adjusted
f 0.46 0.18–1.18 0.10 0.18 0.05–0.64 0.008
ER-negative
KLK15 unadjusted 0.32 0.11–0.96 0.043 0.31 0.097–0.94 0.041
KLK15 adjusted
f 0.25 0.08–0.76 0.015 0.23 0.07–0.76 0.016
PR-positive
KLK15 unadjusted 0.42 0.14–1.25 0.12 0.31 0.07–1.36 0.13
KLK15 adjusted
g 0.56 0.17–1.86 0.34 0.42 0.07–2.45 0.33
PR-negative
KLK15 unadjusted 0.28 0.099–0.84 0.021 0.36 0.14–0.95 0.039
KLK15 adjusted
g 0.24 0.08–0.73 0.012 0.25 0.08–0.78 0.016
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
b Conﬁdence interval of the estimated HR.
cMultivariate models
were adjusted for tumour grade, nodal status, ER, PR, histologic type and age.
dMultivariate models were adjusted for tumour size, nodal status,
ER, PR, histologic type and age.
eMultivariate models were adjusted for tumour size, grade, ER, PR, histologic type and age.
fMultivariate models
were adjusted for tumour size, grade, nodal status, PR, histologic type and age.
gMultivariate models were adjusted for tumour size, grade, nodal
status, ER, histologic type and age.
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Tumour markers assist in evaluating cancer risk, diagnosis, prog-
nosis or response to treatment (Stearns et al, 1998). For breast
cancer, the hormone receptor status is the only recommended
marker for routine use by the American Society of Clinical Oncol-
ogy (Smith et al, 1999) and the College of American Pathologists
Consensus Statement (Fitzgibbons et al, 2000). Additional classical
prognostic markers, including lymph node status, tumour size and
stage, have also proven prognostic importance (Fitzgibbons et al,
2000). Many other potential prognostic markers have been identi-
ﬁed, including p53, c-erbB2, BCL-2, CEA, CA15.3, CA27.29,
cathepsin D and polyadenylate polymerase (Norberg et al, 1996;
ASCO, (1998); Scorilas et al, 1999a,b; 2000; Fitzgibbons et al,
2000; Hamilton and Piccart, 2000). Markers may be predictive of
treatment response e.g., HER-2 evaluation is useful for selection
of patients for Herceptin therapy (Hamilton and Piccart, 2000).
In addition, the identiﬁcation of new prognostic/predictive markers
will contribute to more optimal patient sub-grouping and indivi-
dualisation of treatment strategies (Hamilton and Piccart, 2000).
Furthermore, there is now growing interest in neural networks
which show promise of combining weak, but independent, infor-
mation from various biomarkers to produce a prognostic index
that is more informative than each individual biomarker alone
(Clark et al, 1994). In this study, we show that KLK15 expression
has independent and favourable prognostic value in breast cancer.
One important consideration that must be taken into account is
that large percentage of our study population received adjuvant
therapy, which may be a source of bias.
KLK15 expression is mainly under androgen regulation through
the AR, and to a lesser extent by progestin. Breast cancer is a
hormone-dependent malignancy (Russo and Russo, 1998), and
androgens have been used for treatment of breast cancer, with a
therapeutic efﬁciency comparable to current hormonal therapies
such as tamoxifen (Tormey et al, 1983). Androgen receptors are
present in 70–90% of primary breast tumours (Soreide et al,
1992), and AR is the sole steroid hormone receptor expressed in
about 25% of metastatic deposits (Lea et al, 1989). In addition,
medroxyprogesterone acetate (MPA), a synthetic progestin, is a
commonly used second line hormonal therapy following failure
of tamoxifen. The androgenic side effects of MPA suggest that its
action may in part be mediated by the AR. Identiﬁcation of andro-
gen-regulated genes that mediate the growth-inhibitory effects of
androgens may enable more precise prediction of the response to
hormonal therapies and deﬁne potential new targets for breast
cancer treatment (Birrell et al, 1998). Such new treatments may
be particularly important in metastatic disease, where the AR is
often the sole steroid receptor expressed.
The prognostic value of KLK15 is similar to that of hK3 (PSA)
which is also an independent marker of favourable prognosis in
breast cancer (Yu et al, 1995). In addition to the structural similar-
ity at the mRNA and protein levels, KLK3, KLK2 and KLK15 have
many common features. They are all serine protease genes, located
adjacent to each other on chromosome 19q13.4. In addition, all are
up-regulated by androgens and progestins in breast cancer cell
lines. It is known that hK2 and hK15 can activate hK3 (Takayama
et al, 1997, 2001). Taken together, we hypothesise that these three
kallikreins all regulated by androgens, may play a role in cell prolif-
eration of the breast. In addition, simultaneous measurements of
multiple kallikrein levels in tumour tissues may have more prog-
nostic value than that of each individual kallikrein.
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Figure 5 KLK15 mRNA concentration in the BT-474 cell line 24 h after
dihydrotestosterone (DHT) stimulation with and without blocking with (A)
RU 56,187 and (B) nilutamide. Blockers were added at a concentration of
10
76 M; DHT was added 1 h later, at a concentration of 10
78 M
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Figure 3 KLK15 mRNA concentration in three different breast cancer
cell lines 24 h after stimulation with steroids at a concentration of
10
78 M. DHT, dihydrotestosterone.
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Figure 4 A plot showing the concentration of KLK15 in the BT-474
breast cancer cell line before (0) and at 2, 6, 12 and 24 h after stimulation
with dihydrotestosterone at a concentration of 10
78 M.
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